J. Cooper

发表

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Margaret Burnett, Gavin Giovannoni, 2018, The Lancet.

Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis

A. Nielsen, A. Langer-Gould, K. Edwards, 2012, Multiple sclerosis.

Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.

S. Cole, J. Selhorst, R. Beck, 2002, Annals of neurology.

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

D. Arnold, S. Reingold, C. Pozzilli, 2020, The Lancet Neurology.

Factors that influence adherence with disease-modifying therapy in MS

Arthur L. Allen, G. Cutter, B. Cohen, 2009, Journal of Neurology.

A hormonal therapy for menopausal women with MS: A phase Ib/IIa randomized controlled trial.

J. Graves, S. Zamvil, A. Green, 2022, Multiple sclerosis and related disorders.

IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event

D. Arnold, J. Selhorst, R. Kinkel, 2006, Neurology.

Interferon β‐1a for early multiple sclerosis: CHAMPS trial subgroup analyses

S. Cole, J. Selhorst, R. Beck, 2002 .

Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo groupy

Jeffrey A. Cohen, S. Cole, D. Arnold, 2002, Multiple sclerosis.

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.

J. Selhorst, C. Kollman, R. Kinkel, 2006, Neurology.